Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

← catalyst calendar

NCT05257408

Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →. With Gynecologic Oncology Group.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
381actual
Sites
117
Countries
Argentina, Australia, Belgium +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-06-29actualWhen the study began enrolling
Primary completion2025-03-24actualThe date the last participant is measured for the primary outcome — the readout window
Study completionMar 2026estimatedThe whole study's end, after follow-up
First posted2022-02-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-04-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Ovarian Neoplasm
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms

Interventions

  • Drug: Nab-paclitaxel 80 mg/m^2
  • Drug: Relacorilant 150 mg once daily (QD)
  • Drug: Nab-paclitaxel 100 mg/m^2

Primary outcomes

what the primary-completion date above is the date OF
Progression-free Survival as Assessed by BICR
measured Up to 24 months from enrollment of the last patient
Overall survival
measured Up to 24 months from enrollment of the last patient

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed